Fri Oct 04 04:29:12 UTC 2024: ## Sight Sciences COO Sells Shares, Stock Price Dips

**[City, State] – October 4, 2024** – Sight Sciences, Inc. (NASDAQ: SGHT), an ophthalmic medical device company, saw its stock price dip slightly on Thursday after the company’s Chief Operating Officer, Sam Boong Park, sold 3,403 shares of the company’s stock.

The shares were sold at an average price of $6.08, for a total value of $20,690.24. Following the transaction, Park now owns 254,826 shares of Sight Sciences stock, valued at approximately $1,549,342.08.

The sale was disclosed in a legal filing with the Securities & Exchange Commission, accessible online.

Shares of SGHT traded down $0.18 during Thursday’s trading, closing at $6.00. The stock has a market capitalization of $298.54 million, a price-to-earnings ratio of -5.36, and a beta of 2.71.

While the stock experienced a slight decline, it’s worth noting that Sight Sciences recently reported strong quarterly earnings, beating analysts’ estimates for both earnings per share and revenue. The company also announced a new product launch, further indicating a positive outlook.

However, recent insider selling activity, including the sale by Park and a previous sale by CEO Paul Carlos, may raise concerns among investors.

Despite the recent dip, several hedge funds have increased their stakes in Sight Sciences, demonstrating continued confidence in the company’s long-term prospects.

Sight Sciences continues to develop and commercialize surgical and nonsurgical technologies for the treatment of eye diseases, operating through two segments: Surgical Glaucoma and Dry Eye. The company’s flagship products include the OMNI Surgical System and the SION Surgical Instrument.

Investors will be closely watching to see how the company’s stock performs in the coming months, especially in light of recent insider selling activity and continued product development efforts.

Read More